These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 11693062

  • 1. [Autologous transplantation of peripheral hematopoietic cells and subsequent maintenance therapy with interferon alpha or interferon alpha and dexamethasone in patients with multiple myeloma--results from the 4W randomized clinical trial of the Czech Myeloma Group].
    Krejcí M, Hájek R, Scudla V, Bacovský J, Indrák K, Faber E, Koza V, Schützová M, Kuca B, Sumná E, Franková H, Lehanka F, Gumulec J, Stavarová Y, Rezek Z, Praskac P, Cahová S, Vránová M, Veprek K, Januska J, Kessler P, Pozdĕnová V, Walterová L, Stefánek I, Hausdorf P, Meluzínová I, Novosadová L, Lenícková S, Dusek L, Syobodník A, Králová E, Adam Z, Mayer J, Vorlícek J.
    Vnitr Lek; 2001 Sep; 47 Suppl 1():40-7. PubMed ID: 11693062
    [Abstract] [Full Text] [Related]

  • 2. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M, Burns LJ, Barker JN, Miller JS, Defor TE, Olujohungbe AB, Weisdorf DJ.
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [Abstract] [Full Text] [Related]

  • 3. [High-dose therapy of multiple myeloma with autologous hematopoietic stem cell transplantation and subsequent maintenance therapy with interferon alfa versus interferon alfa and dexamethasone--a randomized clinical study "4W"].
    Mareschová I.
    Vnitr Lek; 1997 May; 43(5):345. PubMed ID: 9601862
    [No Abstract] [Full Text] [Related]

  • 4. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma.
    Lokhorst HM, Sonneveld P, Cornelissen JJ, Joosten P, van Marwijk Kooy M, Meinema J, Nieuwenhuis HK, van Oers MH, Richel DJ, Segeren CN, Veth G, Verdonck LF, Wijermans PW.
    Bone Marrow Transplant; 1999 Feb; 23(4):317-22. PubMed ID: 10100574
    [Abstract] [Full Text] [Related]

  • 5. [Treatment of multiple myeloma with high-dose chemotherapy and transplantation of autologous hematopoietic stem cells and subsequent maintenance therapy with interferon alfa-2b or interferon alfa 2b and dexamethasone. Report of the ongoing study of the "4W" Czech Myeloma Group].
    Adam Z, Krejcí M, Bacovský J, Hejlová N, Kuca B, Svojgrová M, Franková H, Gumulec J, Janca J, Veprek K, Januska B, Lehanka F, Rezek Z, Praskac P, Cahová S, Vránová M, Papajík T, Králová E, Novotná J, Scudla V, Koza V, Drbal J, Faber E, Mareschová I, Hájek R.
    Vnitr Lek; 1998 Jul; 44(7):400-8. PubMed ID: 9748876
    [Abstract] [Full Text] [Related]

  • 6. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
    Kumar L, Raju GM, Ganessan K, Shawgi S, Menon H, Wadhwa J, Sharma A, Singh R, Kochupillai V.
    Natl Med J India; 2003 Jul; 16(1):16-21. PubMed ID: 12715951
    [Abstract] [Full Text] [Related]

  • 7. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
    Mellqvist UH, Lenhoff S, Johnsen HE, Hjorth M, Holmberg E, Juliusson G, Tangen JM, Westin J, Nordic Myeloma Study Group.
    Cancer; 2008 Jan 01; 112(1):129-35. PubMed ID: 17973267
    [Abstract] [Full Text] [Related]

  • 8. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS, Min CK, Cho BS, Lee S, Lee JW, Min WS, Kim CC, Kim M, Kim Y.
    Jpn J Clin Oncol; 2009 Jul 01; 39(7):449-55. PubMed ID: 19487425
    [Abstract] [Full Text] [Related]

  • 9. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS, Kim K, Cheong JW, Min YH, Suh C, Kim H, Jo DY, Ryoo HM, Yoon SS, Lee JH, Korean Multiple Myeloma Working Party.
    Biol Blood Marrow Transplant; 2009 Apr 01; 15(4):463-70. PubMed ID: 19285634
    [Abstract] [Full Text] [Related]

  • 10. [Autologous transplantation of peripheral stem cells in treatment of recurrent multiple myeloma].
    Krejcí M, Adam Z, Mayer J, Hájek R, Vorlícek J.
    Vnitr Lek; 1998 Dec 01; 44(12):698-701. PubMed ID: 10422512
    [Abstract] [Full Text] [Related]

  • 11. Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency.
    Tosi P, Zamagni E, Tacchetti P, Ceccolini M, Perrone G, Brioli A, Pallotti MC, Pantani L, Petrucci A, Baccarani M, Cavo M.
    Biol Blood Marrow Transplant; 2010 Aug 01; 16(8):1115-21. PubMed ID: 20197100
    [Abstract] [Full Text] [Related]

  • 12. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT).
    Björkstrand B, Svensson H, Goldschmidt H, Ljungman P, Apperley J, Mandelli F, Marcus R, Boogaerts M, Alegre A, Remes K, Cornelissen JJ, Bladé J, Lenhoff S, Iriondo A, Carlson K, Volin L, Littlewood T, Goldstone AH, San Miguel J, Schattenberg A, Gahrton G.
    Bone Marrow Transplant; 2001 Mar 01; 27(5):511-5. PubMed ID: 11313685
    [Abstract] [Full Text] [Related]

  • 13. Prolonged survival after intensive therapy and purged ABMT in patients with multiple myeloma.
    Reece DE, Brockington DA, Phillips GL, Barnett MJ, Klingemann HG, Nantel SH, Sutherland HJ, Shepherd JD.
    Bone Marrow Transplant; 2000 Sep 01; 26(6):621-6. PubMed ID: 11041567
    [Abstract] [Full Text] [Related]

  • 14. Pilot study of 13cis-retinoic acid+dexamethasone+alpha interferon as maintenance therapy following high-dose chemotherapy and autologous stem cell transplant for multiple myeloma.
    Friedman J, Khoury H, Adkins D, Devine S, Nervi B, Edwards T, Dipersio J, Vij R.
    Bone Marrow Transplant; 2005 May 01; 35(10):979-84. PubMed ID: 15806132
    [Abstract] [Full Text] [Related]

  • 15. Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
    Lee CK, Barlogie B, Zangari M, Fassas A, Anaissie E, Morris C, Van Rhee F, Cottler-Fox M, Thertulien R, Muwalla F, Mazher S, Badros A, Tricot G.
    Bone Marrow Transplant; 2002 Dec 01; 30(12):873-8. PubMed ID: 12476279
    [Abstract] [Full Text] [Related]

  • 16. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma.
    Cavo M, Zamagni E, Tosi P, Cellini C, Cangini D, Tacchetti P, Testoni N, Tonelli M, de Vivo A, Palareti G, Tura S, Baccarani M.
    Haematologica; 2004 Jul 01; 89(7):826-31. PubMed ID: 15257934
    [Abstract] [Full Text] [Related]

  • 17. alpha-Interferon for remission maintenance: preliminary report on the Southwest Oncology Group Study.
    Salmon SE, Beckord J, Pugh RP, Barlogie B, Crowley J.
    Semin Oncol; 1991 Oct 01; 18(5 Suppl 7):33-6. PubMed ID: 1948127
    [Abstract] [Full Text] [Related]

  • 18. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on Autologous Transplantation in Multiple Myeloma.
    Harousseau JL, Attal M, Divine M, Marit G, Leblond V, Stoppa AM, Bourhis JH, Caillot D, Boasson M, Abgrall JF.
    Stem Cells; 1995 Aug 01; 13 Suppl 2():132-9. PubMed ID: 8520502
    [Abstract] [Full Text] [Related]

  • 19. First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma.
    Abdelkefi A, Torjman L, Ben Romdhane N, Ladeb S, El Omri H, Ben Othman T, Elloumi M, Bellaj H, Lakhal A, Jeddi R, Aissaouï L, Saad A, Hsaïri M, Boukef K, Dellagi K, Ben Abdeladhim A.
    Bone Marrow Transplant; 2005 Aug 01; 36(3):193-8. PubMed ID: 15968290
    [Abstract] [Full Text] [Related]

  • 20. Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT.
    Kumar SK, Dingli D, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Rajkumar SV, Litzow MR, Gertz MA.
    Bone Marrow Transplant; 2008 Jun 01; 41(12):1013-9. PubMed ID: 18332915
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.